Vistin Pharma ASA (OSL:VISTN)

kr 24.6 -0.5 (-1.99%) Market Cap: 1.09 Bil Enterprise Value: 1.09 Bil PE Ratio: 17.88 PB Ratio: 3.51 GF Score: 77/100

Q3 2024 Vistin Pharma ASA Earnings Call Transcript
Oct 31, 2024

kr26.1 (-0.38%)

Earnings
Q2 2024 Vistin Pharma ASA Earnings Call Transcript
Aug 23, 2024

kr23.3 (+4.02%)

Earnings
Q1 2024 Vistin Pharma ASA Earnings Call Transcript
Apr 24, 2024

kr23.5 (-3.29%)

Earnings
Q4 2023 Vistin Pharma ASA Earnings Call Transcript
Feb 16, 2024

kr23.5 (-2.49%)

Earnings
Q3 2023 Vistin Pharma ASA Earnings Call Transcript
Oct 25, 2023

kr23.3 (-2.10%)

Earnings
Half Year 2023 Vistin Pharma ASA Earnings Call Transcript
Aug 23, 2023

kr22.9 (-0.87%)

Earnings
Q1 2023 Vistin Pharma ASA Earnings Call Transcript
Apr 27, 2023

kr21.9 (+5.29%)

Earnings
Q4 2022 Vistin Pharma ASA Earnings Call Transcript
Feb 17, 2023

kr18 (+8.11%)

Earnings
Q3 2022 Vistin Pharma ASA Earnings Call Transcript
Oct 26, 2022

kr13

Earnings
Q2 2022 Vistin Pharma ASA Earnings Call Transcript
Aug 19, 2022

kr16 (+0.31%)

Earnings
Q2 2021 Vistin Pharma ASA Earnings Call Transcript
Apr 27, 2022

kr18.2 (+3.41%)

Earnings
Q4 2021 Vistin Pharma ASA Earnings Call Transcript
Feb 17, 2022

kr18.06 (+0.89%)

Earnings
Q3 2021 Vistin Pharma ASA Earnings Call Transcript
Oct 28, 2021

kr19.38 (-5.46%)

Earnings
Q2 2021 Vistin Pharma ASA Earnings Call Transcript
Aug 19, 2021

kr21.2 (-7.83%)

Earnings

Q2 2022 Vistin Pharma ASA Earnings Call Transcript

Aug 19, 2022 / 06:30AM GMT

Release Date Price: kr16 (+0.31%)

Transcript

Operator

Good day, and thank you for standing by. Welcome to the Vistin Pharma Quarterly Report Q2 202 Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded.

I would now like to turn the conference over to your speaker today, Alexander Karlsen. Please go ahead.

Alexander Karlsen

Vistin Pharma ASA - CFO

Thank you, and good morning, everyone. Welcome to Vistin Pharma's Second Quarter and First Half presentation. Today's presentators will be myself, Alexander Karlsen, the CFO. And with me, I have Magnus Tolleshaug, the CCO and the interim CEO. I will now hand it over to you, Magnus.

Magnus Tolleshaug

Vistin Pharma ASA - Interim CEO, Chief Commercial Officer & Commercial Director

Thank you, Alexander. I will go through the highlights of the second quarter and year-to-date 2022 results. The second quarter ended with a revenue of NOK 69 million versus NOK 67 million in Q2 2021, which represents a 3% increase. Due to the Metformin Expansion Project, ramp-up activities,

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.